What are the opening hours?

Monday 8am - 5pm Tuesday 8am - 5pm Wednesday 8am - 5pm Thursday 8am - 5pm Friday 8am - 5pm Saturday 9am - 6pm Sunday 9am - 6pm

Aspira Women's Health

Home
United States
Bee Cave, TX
Aspira Women's Health

We believe our passion will become evident to you in the level of service that we provide.

Aspira Women's Health is on a mission to globally transform women's health, starting with Ovarian Cancer, and improve survival and life through our innovative health solutions. At Aspira Women's Health, we pride ourselves on being at the forefront of ovarian cancer research and we have a passion for assisting in the delivery of relevant and timely care to your patients. Providing you with the high

est quality diagnostic results is a responsibility that we take very seriously and we are honored that you have chosen us to do so. You can trust the results that ASPIRA LABS provides and take comfort in the knowledge that OVA1 testing is FDA cleared and ASPIRA LABS is certified by Clinical Laboratory Improvement Amendments (CLIA), which means that we adhere to the highest standards in the clinical laboratory industry. Our entire team of business and laboratory professionals is looking forward to working with you. It is important to all of us that you receive exceptional service, so please don’t hesitate to contact us with any comments or concerns that you may have.

02/20/2025

Ova1® is the first and only FDA-cleared, multi-biomarker blood test that helps assess ovarian cancer risk before surgery. It provides objective insights beyond CA-125 alone, empowering healthcare providers to make more informed patient decisions.

When it comes to ovarian cancer, knowledge is power—and early, accurate risk assessment can refine adnexal mass management.

🔗 Learn more about Ova1 and how it can support your practice: https://aspirawh.com/ova1plus/

’sHealth

02/11/2025

📢 Aspira Women's Health Announces New Board Appointment

We welcome Ellen Beausang to our Board of Directors. With extensive leadership experience in diagnostics and healthcare, Ellen will provide valuable insights as we continue expanding our market opportunity and advancing women’s health.

"As we grow our current business lines and develop new diagnostic solutions, Ellen’s expertise will be instrumental," said Michael Buhle, CEO of Aspira Women's Health.

Learn more: https://ow.ly/OUn650UXWyo

01/28/2025

📣 Join Aspira Women’s Health at the Michigan ACOG Annual Section Meeting 2025!
Connect with peers and explore the latest advancements in women’s health. Visit us at our booth! We’re here to answer your questions and share how our OvaSuite℠ innovative solutions can support your practice and improve patient outcomes.

📅 Don’t miss this opportunity to learn, network, and advance care.

We look forward to seeing you there!

01/23/2025

Our clinical study, "Ovarian Cancer surgical consideration is markedly improved by the neural network powered-MIA3G multivariate index assay," highlights the promising potential of MIA3G in reducing unnecessary surgeries for adnexal masses. This innovative tool could help avoid premature surgeries and known side effects like surgical menopause.

Stay tuned for more valuable insights, expert advice, and tools for informed ovarian health management! Read the study here: https://lnkd.in/ew6Fjf4m

01/20/2025

🌟 Honoring the Legacy of Dr. Martin Luther King Jr. 🌟

Today, we remember and celebrate the extraordinary life and vision of Dr. Martin Luther King Jr. His unwavering dedication to equality, justice, and compassion continues to inspire us in every aspect of our work.

At Aspira Women’s Health, we strive to embody his principles by advocating for health equity and empowering women with access to innovative solutions for gynecologic care. Together, we can build a future where all women, regardless of background, have the opportunity to live healthier lives.

01/15/2025

Aspira Women's Health has received a $10M federal grant to develop a revolutionary blood test for endometriosis detection.

This advancement could reduce diagnosis time from 11 years to just 48 hours, potentially helping millions of women receive earlier care. Connecticut leads the way as the first state with a dedicated endometriosis biorepository to support this crucial research.

Read this article to learn more: https://www.ctpost.com/news/article/shelton-aspira-health-endometriosis-funding-19944183.php?utm_campaign=CMS%20Sharing%20Tools%20(Premium)&utm_source=share-by-email&utm_medium=email

01/10/2025

📢 Exciting leadership updates at Aspira Women's Health:

Mike Buhle joins Aspira as SVP of Commercial Operations, bringing over 20 years of experience in clinical diagnostics and life science technology solutions. Mike's commercial expertise spans precision medicine, oncology, rare diseases, and women’s healthcare.

We're also pleased to announce that James O’Brien, who brings 30+ years of financial expertise and experience in the biotech and pharmaceutical industries, will join as CFO advisor. Read the press release: https://feeds.issuerdirect.com/news-release.html?newsid=5505294785867855

Both leaders will join Dr. Sandra Milligan, Interim CEO, at JPM Healthcare Conference on Jan 13-16 in San Francisco.

Contact our IR team through mike.cavanaugh@icrhealthcare.com to schedule a meeting with us.

News Release

01/09/2025

🤝 Connect with Aspira Women's Health at !
Meet our Interim CEO, Dr. Sandra Milligan, at the J.P. Morgan Healthcare Conference in San Francisco (January 13-16).

Dr. Milligan will be available to discuss:

• Our innovative AI-enabled diagnostic portfolio OvaSuite℠
• Our development pipeline in ovarian cancer and endometriosis
• Partnership opportunities in women's health diagnostics
• Our vision for transforming gynecologic health

📅 Date: January 13-16, 2025
📍 Location: San Francisco, CA
Would you be interested in scheduling a meeting? Contact our IR team through mike.cavanaugh@icrhealthcare.com

01/01/2025

Highlight #1: A $10 Million Dollar Step Toward Transforming Women’s Health

Aspira Women’s Health secured a remarkable $10 million dollar award from the Advanced Research Projects Agency for Health initiative, marking a pivotal moment in 2024. With our first milestone already achieved, this funding propels us toward revolutionizing ovarian care and transforming women’s health. What an incredible way to end the year!

Read more about this milestone in our press release located in the News section of our Investors page: https://ir.aspirawh.com/press-release/aspira-womens-health-successfully-reaches-the-first-milestone-of-the-arpa-h-10-million-award/?refresh=1734978573333

12/30/2024

Highlight #2: Expansion of OvaWatch®

Aspira Women’s Health received approval from the NYSDOH - New York State Health Department for OvaWatch® and its longitudinal monitoring feature. This milestone reflects our ongoing commitment to providing advanced solutions for ovarian health and improving long-term patient care.

Read more about this achievement in our press release here: https://ir.aspirawh.com/press-release/aspira-womens-health-receives-approval-from-new-york-state-department-of-health-for-ovawatch/?refresh=1735593896381

12/27/2024

Highlight #3: Advancing Women’s Health Through Research

Aspira Women’s Health announced the publication of research demonstrating that OvaWatch® can help stratify risk in patients with an adnexal mass, potentially reducing surgical backlogs and unnecessary referrals. This groundbreaking study highlights how OvaWatch® is improving care efficiency and patient outcomes.

Read more about this publication in our press release here: https://ir.aspirawh.com/press-release/aspira-womens-health-announces-publication-of-two-ovawatch-peer-reviewed-manuscripts/?refresh=1734978295971

12/26/2024

Highlight #4: Expanding Our Collaboration for Women’s Health

Aspira Women’s Health expanded its co-marketing and distribution collaboration with BioReference® to include OvaWatch® in New York and New Jersey. This growth further strengthens our commitment to providing innovative women’s health solutions.

Read more about this expansion in our press release here: https://ir.aspirawh.com/press-release/aspira-womens-health-expands-co-marketing-and-distribution-collaboration-with-bioreference-to-include-ovawatch/?refresh=1735250458630

Address

Bee Cave, TX

Opening Hours

Monday	8am - 5pm
Tuesday	8am - 5pm
Wednesday	8am - 5pm
Thursday	8am - 5pm
Friday	8am - 5pm
Saturday	9am - 6pm
Sunday	9am - 6pm

Telephone

+18442774721

Website

https://www.aspirawh.com/

Alerts

Be the first to know and let us send you an email when Aspira Women's Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Aspira Women's Health: